APA (7th ed.) Citation

Tabernero, J., Satoh, T., Dasari, A., Lonardi, S., Eng, C., Garcia-Carbonero, R., . . . Van Cutsem, E. (2024). Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial. Journal of clinical oncology, 42(3_suppl), 116. https://doi.org/10.1200/JCO.2024.42.3_suppl.116

Chicago Style (17th ed.) Citation

Tabernero, Josep, et al. "Quality-adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) Analysis of Fruquintinib + Best Supportive Care (BSC) Compared with Placebo + BSC in Metastatic Colorectal Cancer (mCRC): Results from the FRESCO-2 Trial." Journal of Clinical Oncology 42, no. 3_suppl (2024): 116. https://doi.org/10.1200/JCO.2024.42.3_suppl.116.

MLA (9th ed.) Citation

Tabernero, Josep, et al. "Quality-adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) Analysis of Fruquintinib + Best Supportive Care (BSC) Compared with Placebo + BSC in Metastatic Colorectal Cancer (mCRC): Results from the FRESCO-2 Trial." Journal of Clinical Oncology, vol. 42, no. 3_suppl, 2024, p. 116, https://doi.org/10.1200/JCO.2024.42.3_suppl.116.